Heregulin Activity Assays for Residual Testing of Cell Therapy Products

dc.contributor.authorMonje, Paula V.
dc.contributor.authorBacallao, Ketty
dc.contributor.authorAparicio, Gabriela I.
dc.contributor.authorLalwani, Anil
dc.contributor.departmentNeurological Surgery, School of Medicineen_US
dc.date.accessioned2023-04-03T19:42:13Z
dc.date.available2023-04-03T19:42:13Z
dc.date.issued2021-11-12
dc.description.abstractBackground: Heregulin is a ligand for the protooncogene product ErbB/HER that acts as a key mitogenic factor for human Schwann cells (hSCs). Heregulin is required for sustained hSC growth in vitro but must be thoroughly removed before cell collection for transplantation due to potential safety concerns. The goal of this study was to develop simple cell-based assays to assess the effectiveness of heregulin addition to and removal from aliquots of hSC culture medium. These bioassays were based on the capacity of a β1-heregulin peptide to elicit ErbB/HER receptor signaling in adherent ErbB2+/ErbB3+ cells. Results: Western blotting was used to measure the activity of three different β1-heregulin/ErbB-activated kinases (ErbB3/HER3, ERK/MAPK and Akt/PKB) using phospho-specific antibodies against key activating residues. The duration, dose-dependency and specificity of β1-heregulin-initiated kinase phosphorylation were investigated, and controls were implemented for assay optimization and reproducibility to detect β1-heregulin activity in the nanomolar range. Results from these assays showed that the culture medium from transplantable hSCs elicited no detectable activation of the aforementioned kinases in independent rounds of testing, indicating that the implemented measures can ensure that the final hSC product is devoid of bioactive β1-heregulin molecules prior to transplantation. Conclusions: These assays may be valuable to detect impurities such as undefined soluble factors or factors for which other biochemical or biological assays are not yet available. Our workflow can be modified as necessary to determine the presence of ErbB/HER, ERK, and Akt activators other than β1-heregulin using native samples, such as fresh isolates from cell- or tissue extracts in addition to culture medium.en_US
dc.eprint.versionFinal published versionen_US
dc.identifier.citationMonje PV, Bacallao K, Aparicio GI, Lalwani A. Heregulin Activity Assays for Residual Testing of Cell Therapy Products. Biol Proced Online. 2021;23(1):22. Published 2021 Nov 12. doi:10.1186/s12575-021-00157-5en_US
dc.identifier.urihttps://hdl.handle.net/1805/32200
dc.language.isoen_USen_US
dc.publisherBMCen_US
dc.relation.isversionof10.1186/s12575-021-00157-5en_US
dc.relation.journalBiological Procedures Onlineen_US
dc.rightsAttribution 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.sourcePMCen_US
dc.subjectSchwann cellsen_US
dc.subjectPeripheral nerveen_US
dc.subjectIn vitro cultureen_US
dc.subjectAutologous cell therapyen_US
dc.subjectResidual testingen_US
dc.subjectQuality controlen_US
dc.subjectSignal transductionen_US
dc.subjectKinase activationen_US
dc.subjectWestern bloten_US
dc.titleHeregulin Activity Assays for Residual Testing of Cell Therapy Productsen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
12575_2021_Article_157.pdf
Size:
3.25 MB
Format:
Adobe Portable Document Format
Description:
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.99 KB
Format:
Item-specific license agreed upon to submission
Description: